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Background: The impact of lung transplantation on end of life care in cystic fibrosis (CF) has not been widely investigated.
Methods: Information about end of life care was collected from records of all patients who died in our hospital from complications of CF
between 1995 and 2005. Transplant and non-transplant patients were compared.
Results: Of 38 patients who died, 20 (53%) had received or were awaiting lung transplantation (“transplant” group), and 18 (47%) were not
referred, declined transplant, or were removed from the waiting list (“non-transplant”). Transplant patients were more likely than non-transplant
patients to die in the intensive care unit (17 (85%) versus 9 (50%); P=0.04). 16 (80%) transplant patients remained intubated at or shortly before
death, versus 7 (39%) non-transplant patients (P=0.02). Do-not-resuscitate orders were written later for transplant patients; 12 (60%) on the day
of death versus 5 (28%) in non-transplant patients (P=0.02). Transplant patients were less likely to participate in this decision. Alternatives to
hospital death were rarely discussed.
Conclusions: Receiving or awaiting lung transplantation affords more aggressive inpatient end of life care. Despite the chronic nature of CF
and knowledge of a shortened life span, discussions about terminal care are often delayed until patients themselves are unable to participate.
© 2007 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; End of life care; Lung transplantationCystic fibrosis (CF) is a life span-limiting genetic disease
with predicted median age of survival of 36.8 years in the
United States [1]. The natural history of CF is a progressive
decline in lung function secondary to chronic infection, with
death resulting from respiratory failure in most patients [2].
Advancements in CF care, including improved pulmonary
and nutritional therapies, have led to improved survival over
time. In addition, lung transplant is a therapeutic option
which may improve survival [3] and quality of life [3–5] for☆ Data previously presented at the 2006 North American Cystic Fibrosis
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doi:10.1016/j.jcf.2007.03.005some patients. Since the reality of the disease is that it
generally leads to death at an early age, physicians who
provide care for CF patients should be prepared to help
manage both the medical and psychological aspects of care
at the end of life.
It has been suggested that end of life care in CF does not
fit the traditional model of palliative care [6]. CF patients are
more likely to die in the hospital than at home or in hospice
care facilities, and tend to receive aggressive medical care
[7]. Whether death typically occurs in the acute care setting
because of patient wishes or because of lack of alternatives
has not been described. Lung transplant patients who do not
survive may be even more likely to die in the hospital,
specifically in the intensive care unit (ICU) [8]. This may be
related to assumptions medical providers make about patient
desires for treatments at the end of life. The aims of this study
were (1) to assess various aspects of end of life care ined by Elsevier B.V. All rights reserved.
Fig. 1. Selection of the study population.
Table 1
Classification of patients according to lung transplant status
Transplant status Number of subjects (%)
“Transplant” 20 (53%)
Awaiting first transplant 10
Received one transplant, listed for second 6
Received two transplants 4
“Non-transplant” 18 (47%)
Not referred for transplant a 14
Removed from transplant list b 1
Declined transplant c 3
a Seven did not meet criteria for referral, 4 were not referred because of non-
adherence to medical therapies, and 3 were not referred for undocumented
reasons.
b Removed from transplant list because of non-adherence to medical
therapies.
c None had previously undergone a lung transplant.
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whether differences exist with regard to end of life care in
transplant and non-transplant patients, and (3) to assess
whether alternatives to death in the acute care setting are
discussed and offered to CF patients.
1. Methods
We reviewed the medical records of all 119 patients who
died from complications of CF between November 1995 and
November 2005 while under the care of the University of
North Carolina Cystic Fibrosis Center (Fig. 1). Seventy-
seven of these patients received CF-related care at our center
for a minimum of 2 years preceding death. Little information
was available about the 33 patients who died outside the
institution. Many of these patients lived a great distance from
our center, thus were more likely to have died in hospitals in
their communities rather than at our institution. Forty-four of
the remaining patients died as inpatients at our institution
during this period, and these were the patients in whom there
was sufficient information documented about end of life care
to complete the chart review.
From this group of 44 patients, 6 were excluded because
they either did not survive to hospital discharge following
lung transplant (5 patients) or had undergone lung transplant
within the preceding 6 months (1 patient), a factor which
would likely influence decision-making about end of life
care. Information about the remaining 38 patients was in-
cluded in the analysis. These 38 patients were divided intotwo groups based on their lung transplant status. Twenty
patients (53%) who had either received or were awaiting lung
transplant comprised the “transplant” group. These patients
were grouped because of presumably similar exposures to
discussions about lung transplantation and to care by our
transplant team, which differs from the CF center medical
team. The “non-transplant” group included 18 patients (47%)
who were not referred for transplant, were considered for
transplant but subsequently removed from the transplant
list, or declined transplant (Table 1). Patients younger than
18 years were considered “children” for the analysis.
Table 2
Comparison of characteristics of transplant and non-transplant patients
Characteristic “Transplant”,
N=20
“Non-transplant”,
N=18
P
value a
Mean age at death (years) 24.1±8.8 21.6±10.1 0.42
Children – n (%) 6 (30) 8 (44) 0.36
Gender – Male – n (%) 7 (35) 8 (44) 0.55
Race – Caucasian – n (%) 20 (100) 18 (100) –
Genotype – n (%)
Homozygous deltaF508 14 (70) 9 (50) 0.37
Other 6 (30) 9 (50)
Primary pathogen – n (%)
Pseudomonas aeruginosa 16 (79) 12 (67) 0.67
Burkholderia cepacia
complex b
3 (16) 5 (28)
Other 1 (5) 1 (5)
Lung function – n (%)
FEV1 b30% predicted 17 (85) 12 (67) 0.35
Unknown c – 1 ( 5)
Cause of death – n (%)
Respiratory failure 15 (75) 16 (89) 0.27
Sepsis 5 (25) 2 (11)
Distance from center – n (%)
In-state, less than 100 miles 10 (50) 10 (56)
In-state, more than 100 miles 7 (35) 7 (39) 0.64
Out of state 3 (15) 1 (5)
Educational level (adults) – n (%)
Less than high school 1 (7) 2 (20)
High school degree 1 (7) 6 (60) 0.02
College enrolled or graduate 8 (57) 2 (20)
Unknown c 4 (29) –
Marital status (adults) – n (%)
Married 6 (43) 4 (40)
Divorced or separated 2 (14) – 0.41
Single 6 (43) 6 (60)
Family situation (children) – n (%)
Intact family 3 (50) 4 (50) – –
Single parent 3 (50) 4 (50)
Other CF in family – n (%)
Yes, sibling 3 (15) 3 (17)
Yes, other relative 3 (15) 4 (22) 0.86
Unknown c 4 (20) 2 (11)
Prior CF death in family – n (%)
Yes, sibling 2 (10) 1 (5)
Yes, other relative – 4 (22) 0.16
Unknown c 5 (25) 3 (17)
a Overall P value, determined by χ2 test.
b Prevalence of B. cepacia complex was 6.6% at our center in 2005, and
prevalence of B. cepacia Genomovar III was 3.6%.
c Unknown implies not documented.
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demographic information; disease-specific information such
as lung function and respiratory pathogens; lung transplant
status; and information concerning end of life care, including
setting of death, the use of mechanical ventilation, docu-
mentation of advanced directives, timing of do-not-resusci-
tate (DNR) orders, and patient involvement in discussions
about terminal care.
For the purposes of this study, the term “advance di-
rectives”was defined as previously discussed wishes for life-
sustaining treatments, and implies direct communication
with the patient regarding such wishes. “Final resuscitation
status” was defined as the resuscitation status documented in
the medical record which determined whether or not
resuscitation was attempted in the event of a cardiopulmo-
nary arrest. “Full code” status was defined as desiring an
attempt at resuscitation in the event of a cardiopulmonary
arrest, and a “DNR” status was defined as desiring no in-
tubation or resuscitation efforts. Those who remained in-
tubated at the time of death or until shortly before, such that
their death occurred due to withdrawal of ventilatory sup-
port, were considered “intubated” for the analysis.
For this descriptive study, summary statistics were used
to analyze all study variables. Differences in categorical
variables and trends were compared using χ2 for larger
samples and Fisher's Exact Test for smaller samples. For
categorical variables with more than two categories, P-value
for χ2 with more than two degrees of freedom was ca-
lculated, and individual pairs were tested in subsets using χ2
or Fisher's Exact Tests. Missing variables were excluded
from the analysis.
The study was approved by the biomedical institutional
review board of the University of North Carolina, and was
conducted according to its guidelines for protection of pa-
tient confidentiality.
2. Results
2.1. Patient characteristics
For the study population as a whole, the mean age at death
was 22.9 years (range 8 to 41 years). Fourteen (37%) patients
were children (age b18 years). The FEV1 was less than 30%
predicted, a factor often used in considering patients for
lung transplant [7], in 29 patients (76%) overall. The most
common primary respiratory pathogen was Pseudomonas
aeruginosa (73%), and Burkholderia cepacia complex
organisms were cultured in 22% of patients. Respiratory
failurewas the cause of death in 31 (82%) patients overall, with
sepsis syndromes responsible for the remainder of deaths.
The patients were divided into “transplant” and “non-
transplant” groups as previously described. There were 6
children and 14 adults in the transplant group, and 8 children
and 10 adults in the non-transplant group. Comparisons
between the two groups are shown in Table 2. The groups did
not differ substantially in terms of their basic characteristicsexcept for education, with significantly more transplant
patients having enrolled in or graduated from college than
the non-transplant group. The mean time between transplant
and death was 4.1 years (range 0.6–10.1 years).
2.2. Level of care at the end of life
Characteristics of end of life care in both transplant and
non-transplant patients who died in the hospital are sum-
marized in Table 3. Transplant patients were significantly
more likely to die in the ICU (85% versus 50%; P=0.04) and
Table 3
Characteristics of end of life care in transplant versus non-transplant patients
who died during hospitalization
Characteristic of end of life care “Transplant”,
N=20
“Non-transplant”,
N=18
P
value a
Setting of death – n (%)
Hospital ward 3 (15%) 9 (50%) 0.04 b
Intensive care unit 17 (85%) 9 (50%)
Intubation status – n (%)
Not intubated 4 (20%) 11 (61%) 0.02b
Intubated 16 (80%) 7 (39%)
Advance directives – n (%)
Unknown or not documented
in chart
6 (30%) 6 (33%)
Full code 12 (60%) 2 (11%) b0.01 c
Do not resuscitate 0 (–) 5 (28%)
Discussed but no
decision made
2 (10%) 5 (28%)
Final resuscitation status – n (%)
Resuscitation attempted 3 (5%) 0 (–)
DNR order written,
death occurred spontaneously
8 (40%) 13 (72%) 0.07
DNR order written, intensive
support withdrawn
9 (45%) 5 (28%)
Patient participated in discussion regarding
final resuscitation status – n (%)
Unknown or not documented
in chart
13 (65%) 7 (39%)
Yes 3 (15%) 11 (61%) b0.01 d
No 4 (20%) 0 (–)
Timing of DNR order – n (%)
At/before hospital admission 0 (–) 2 (11%)
Before day of death 5 (25%) 11 (61%) 0.02
On day of death 12 (60%) 5 (28%)
Never (full code) 3 (15%) 0 (–)
a Overall P value, determined by χ2 test unless otherwise noted.
b Fisher's Exact Test.
c Transplant and non-transplant patients differed with regard to desiring a
“full code” status versus a DNR status (Pb0.01) and desiring DNR status
versus being undecided (Pb0.01), with transplant patients more likely to
desire a full code and less likely to be undecided.
d Transplant and non-transplants patients differed with regard to
involvement in decisions about their ultimate resuscitation status. Transplant
patients were less often documented to be involved in the discussion (Pb0.01).
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versus 39%; P=0.02) than non-transplant patients. Non-
invasive ventilation was used in 3 non-transplant patients, 2
of whom died on a hospital ward and 1 in the ICU. No
transplant patients were using non-invasive ventilation at the
time of death. Of those who died in the ICU, all but 1 (94%) of
the transplant patients were intubated at the time of death or
shortly before, versus only 2 (29%) of the non-transplant
patients (Pb0.01). Age, gender, marital status or family
situation, family history of CF, and a history of prior CF
deaths in the family were not independently associated with
setting of death or intubation status. A higher level of
education was associated with increased likelihood of dying
in the ICU and being intubated at or shortly before death,
consistent with the fact that there were more patients who had
achieved a higher level of education in the transplant group.2.3. Advance directives and resuscitation status
Discussions regarding advance directives were documen-
ted in a similar proportion of transplant and non-transplant
patients (70% versus 67%; P=0.83). The timing of such
discussions was highly variable. Transplant and non-trans-
plant patients differed with regard to desired resuscitation
status, with transplant patients more often designating a full
code status (60% versus 11%; Pb0.01). Transplant patients
were less likely than non-transplant patients to be undecided
with regard to desire for resuscitation (10% versus 28%;
Pb0.01).
At the time of death, all but 3 patients (all 3 of whom were
awaiting first lung transplant) had a DNR status. There was a
trend toward more transplant than non-transplant patients
dying via withdrawal of ventilatory support (45% versus
28%; P=0.13) following the decision to establish a resus-
citation status of DNR, with the remainder of both groups
(with the exception of the 3 transplant patients in whom
resuscitation was attempted) dying after a DNR order was
written but not requiring withdrawal of invasive support.
Transplant patients were more likely to have a DNR order
written on the day of death than before the day of death (60%
versus 28%; P=0.05). None of the transplant patients had a
DNR order written at the time of admission to the hospital.
Comparison of advance directives to final resuscitation
status revealed that the 3 patients in whom resuscitation was
attempted at the time of death had desired a full code status at
the time advance directives were determined. All 5 who had
designated a DNR status maintained this status at the time of
death. Eleven patients who had designated a full code status
were ultimately changed to DNR status. All 19 patients in
whom advance directives were not documented or no deci-
sion had been made ultimately had a DNR status.
Documentation of patient involvement in discussions
about wishes for treatments at the end of life and determining
their final resuscitation status was examined. Transplant
patients were less likely to be involved in such discussions
(15% versus 61%; Pb0.01). There was less documentation
of such discussions in the transplant group (35% versus 61%;
Pb0.01), most likely because more of these patients were
intubated and sedated, thus unable to participate. When
discussions were documented, adults and children were
equally likely to be involved, but the actual frequency of
documentation of whether or not children themselves were
involved in such discussions was quite low (3 children
(21%), versus 15 adults (63%); Pb0.01).
2.4. Alternatives to inpatient care
Hospice care was not utilized by any of the patients in the
study population as all died in the acute care setting. This
option was discussed with 1 adult transplant patient and 1
adult non-transplant patient, both of whom died outside of
the ICU. Interest in this option was expressed by the trans-
plant patient, but death occurred before arrangements could
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the hospital.
3. Discussion
It has been reported that patients with CF often receive
their end of life care in the hospital, and tend to receive
aggressive care [7]. This study supports these findings, and
provides new insight by demonstrating that differences exist
between transplant and non-transplant patients with regard
to end of life care. At our center over the period studied,
transplant patients were more likely to die in the ICU and to
be treated with mechanical ventilation. They were more
likely to desire attempts at resuscitation, and were less likely
to participate in discussions which precluded this from
happening during a severe, terminal illness. They were less
likely to be able to communicate effectively with medical
providers and with family members and friends around the
time of death. As therapeutic care is a component of pal-
liative care in patients with CF [6], and, in some cases, lung
transplant remains a viable option until other major com-
plications of CF or previous lung transplant ensue, a more
aggressive approach to care may be appropriate. This di-
rection of care, if chosen, should not necessarily limit patient
participation in discussions about preferences for treatments
at the end of life.
Our study has limitations which must be considered when
interpreting the findings. First, our study is a retrospective
chart review, and relies on documentation by physicians and
other CF care providers. Thus, it only reflects the perspective
of certain members of the medical team. In addition, the end
of life care of a large number of patients who died under
the care of our CF center was not documented at all, as it
occurred outside of our institution. We cannot account for the
circumstances of death of these patients. Thirdly, we pre-
sume that patients self-select for transplant to some degree,
such that our comparison groups (transplant versus non-
transplant) are not equivalent. Thus, our statistical compar-
isons are for descriptive purposes only.
Another limitation is that our institution is a lung transplant
center which accepts referrals from a large regional territory
as well as from across the country, and has in the past offered
lung transplantation to some patients infected with B. cepacia,
a pathogen that confers increased mortality in CF [9,10] and is
associated with poorer lung transplant outcomes [11–13].
Thus, this population may not be representative of the overall
population of patients with CF dying in the United States. The
high rate of infection with B. cepacia in our population and
the propensity for infection with this organism to cause more
severe illness may have affected the level of care offered to
some our patients, whether or not they were candidates for or
recipients of lung transplant.
Although the outcomes of patients with CF who undergo
invasive therapies for respiratory failure has historically been
poor [14], these outcomes may be improving over time, such
that this level of care may be felt to be appropriate undersome circumstances [15–17]. Patients who have survived
previous illnesses involving the use of invasive or non-
invasive mechanical ventilation may, in particular, be more
willing to undergo such treatments. During the time period
reviewed, non-invasive ventilation has been described as a
therapy and possible bridging mechanism to lung transplant
in patients with CF and acute respiratory failure [18,19], but
this strategy was not utilized in our population as all patients
in this category were too ill for this therapy to be effective. In
our analysis, no obvious change in level of care over the
period of time studied was apparent.
Despite these limitations, our findings have important
implications and suggest further areas of study. One such
area is when to address preferences for treatments at the
end of life. Patients with CF have known, often for a large
portion of their lives, that they have a life span-limiting
disease, but there are many potential barriers to communi-
cation about end of life issues. For example, the hope offered
by improved therapies and lengthening of the life span in
patients with CF may affect the ability and desire of both
patients and physicians to have such discussions. Aggressive
management strategies such as lung transplant may seem
inconsistent with discussion of end of life care. Recent data
that brings into question whether lung transplant improves
survival in certain patients [13] may prompt CF physicians to
reconsider their approach to discussions about transplant. It
is important to discuss transplant outcomes in terms of both
survival and quality of life. Preferences for treatments at the
end of life are a logical inclusion in such discussions, but as
evidenced by our population of dying patients, if discussions
about end of life care are not held before the time of trans-
plant referral, a substantial proportion of patients may not
benefit from such discussions. Enhancing communication
about such issues may be beneficial for patients, families and
providers alike, and may facilitate the development of mod-
els of end of life care for patients with CF [20].
Investigation of alternatives to dying in the hospital is also
warranted. Studies of inpatient end of life care for other
diseases have revealed discordance among patients, families
and physicians with regard to symptom assessment and
management [21–23] and preferences for life-sustaining
treatments [23]. In addition, those who experience the death
of a hospitalized family member often express dissatisfaction
with care at the end of life [22,24,25]. Given that many
patients with CF die in the hospital, they may be at risk for
receiving unwanted or feeling dissatisfied with end of life
care. These risks may be even greater for lung transplant
patients. Although not studied in CF, it is well established in
many other conditions that patients prefer to die at home or
in a hospice facility than in the acute care setting [26–29].
Home care for acute CF-related illnesses is commonly
practiced [30–35], and hospice services are becoming more
widely available for patients with other chronic diseases
[36,37]. In general, however, the populations served by
hospice are older and the diseases leading to their deaths,
even when chronic, are not comparable to CF. Despite these
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preferable for all patients with CF. Barriers to home care and
referral to hospice programs may exist. It is important for
physicians to assess the wishes of their patients at a time
when patients are able to consider and investigate their
options and to express their wishes.
4. Conclusion and authors' recommendations
In summary, we have found that patients with CF who die
in the hospital, particularly those who have undergone or are
awaiting lung transplant, receive aggressive care at the end
of life and often are unable to participate in discussions and
decision-making surrounding end of life care. Given the
limited published information in this area, examining these
issues at other centers and comparing experiences may pro-
vide useful insights. Based on our findings and experience,
we recommend the following:
1. Caregivers should document patient and family preferences
for end of life care and the use of life-sustaining treatments
in a readily accessible section of the medical record.
2. It may be helpful to begin to address preferences for life-
sustaining treatments as a part of routine care before
patients become terminally ill, as well as at times of
deterioration in health and as part of the lung transplant
referral process.
3. Care centers should develop strategies to enhance in-
formed decision making and communication. Patient,
family and medical provider satisfaction should be eval-
uated before and after interventions to help assess the
value of these strategies.
4. Further research is needed regarding the important
factors in decision making about end of life care in CF,
both from the perspectives of patients and of the health
care team.
Seeking the perspectives of patients and families would
help characterize their wishes regarding end of life care and
the effects that discussions about end of life care might have
on perceived quality of life, compliance with therapies, and
decision-making regarding lung transplant. Assessing phy-
sician approaches to discussions about end of life care in
conjunction with the information offered by patients and
families may help determine the optimal timing and ap-
propriate content of such discussions. This information could
be used to improve the quality of care we offer to patients
with CF at the end of life.
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